Report copyright - Dr Moncef Slaoui - GSK · • Non-live, recombinant, 2-dose, adjuvanted vaccine • Excellent efficacy across all age groups, ~97% • Acceptable safety and tolerability • Ongoing
Please pass captcha verification before submit form
Please pass captcha verification before submit form